<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5DE1F5DE-C065-43EE-8480-DC51E4963DFB"><gtr:id>5DE1F5DE-C065-43EE-8480-DC51E4963DFB</gtr:id><gtr:name>Government of Finland</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/26612066-15AD-43AC-951B-F0DA5B64F2C3"><gtr:id>26612066-15AD-43AC-951B-F0DA5B64F2C3</gtr:id><gtr:name>Glaucoma Australia</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7008F77D-D7F3-4558-AEE7-9195B7890A2D"><gtr:id>7008F77D-D7F3-4558-AEE7-9195B7890A2D</gtr:id><gtr:name>Moorfields Eye Hospital NHS Foundation Trust</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5DE1F5DE-C065-43EE-8480-DC51E4963DFB"><gtr:id>5DE1F5DE-C065-43EE-8480-DC51E4963DFB</gtr:id><gtr:name>Government of Finland</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/26612066-15AD-43AC-951B-F0DA5B64F2C3"><gtr:id>26612066-15AD-43AC-951B-F0DA5B64F2C3</gtr:id><gtr:name>Glaucoma Australia</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7008F77D-D7F3-4558-AEE7-9195B7890A2D"><gtr:id>7008F77D-D7F3-4558-AEE7-9195B7890A2D</gtr:id><gtr:name>Moorfields Eye Hospital NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/46C22D4F-8FCD-423E-B669-130A2D6A8C18"><gtr:id>46C22D4F-8FCD-423E-B669-130A2D6A8C18</gtr:id><gtr:firstName>Rodolfo</gtr:firstName><gtr:surname>hernandez</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F5AA3737-7D86-4CC6-88DB-E6B1316DA0AF"><gtr:id>F5AA3737-7D86-4CC6-88DB-E6B1316DA0AF</gtr:id><gtr:firstName>Augusto</gtr:firstName><gtr:surname>Azuara-Blanco</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/01DC8CAE-C811-4AC1-8168-FD30B989B962"><gtr:id>01DC8CAE-C811-4AC1-8168-FD30B989B962</gtr:id><gtr:firstName>R</gtr:firstName><gtr:surname>Wormwold</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/29413585-0F3D-4BA3-B18F-9F453E47D6BD"><gtr:id>29413585-0F3D-4BA3-B18F-9F453E47D6BD</gtr:id><gtr:firstName>Craig</gtr:firstName><gtr:surname>Ramsay</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9ED0F1CA-38BA-4436-91AC-421777202D73"><gtr:id>9ED0F1CA-38BA-4436-91AC-421777202D73</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Norrie</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/488FC86F-BFA0-4AEE-ADAA-3F0A6B4D18BE"><gtr:id>488FC86F-BFA0-4AEE-ADAA-3F0A6B4D18BE</gtr:id><gtr:firstName>Luke</gtr:firstName><gtr:surname>Vale</gtr:surname><gtr:orcidId>0000-0001-8574-8429</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CDF3C9AA-96AE-4DF6-9964-833B9A391E98"><gtr:id>CDF3C9AA-96AE-4DF6-9964-833B9A391E98</gtr:id><gtr:firstName>Alexandra</gtr:firstName><gtr:surname>Greene</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4E93E1F0-1ED3-416B-9579-ACC67DF423DD"><gtr:id>4E93E1F0-1ED3-416B-9579-ACC67DF423DD</gtr:id><gtr:firstName>Jennifer</gtr:firstName><gtr:surname>Burr</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/70CA9086-C260-4814-94F0-F5A8114F1D41"><gtr:id>70CA9086-C260-4814-94F0-F5A8114F1D41</gtr:id><gtr:firstName>Roger</gtr:firstName><gtr:otherNames>Alan</gtr:otherNames><gtr:surname>Hitchings</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/26310B71-5108-4FEA-8F7D-AA05CA2A0FA3"><gtr:id>26310B71-5108-4FEA-8F7D-AA05CA2A0FA3</gtr:id><gtr:firstName>Marion</gtr:firstName><gtr:otherNames>K</gtr:otherNames><gtr:surname>Campbell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/777A6DED-82EF-49B2-8A20-40AC24C8D021"><gtr:id>777A6DED-82EF-49B2-8A20-40AC24C8D021</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Crabb</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C17736A4-8483-4B79-B340-91EBC21B08EE"><gtr:id>C17736A4-8483-4B79-B340-91EBC21B08EE</gtr:id><gtr:firstName>Jilllian</gtr:firstName><gtr:otherNames>Joy</gtr:otherNames><gtr:surname>Francis</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701759"><gtr:id>B785576A-86ED-44A1-8C59-8936212E80F2</gtr:id><gtr:title>Developing the intervention &amp;amp; outcome components of a proposed RCT of screening for open angle glaucoma</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701759</gtr:grantReference><gtr:abstractText>Open angle glaucoma (OAG) is a common cause of blindness. Many people do not know they are developing OAG and miss out on the potential benefit of early treatment. This study develops the design for a randomised controlled trial (RCT) studying screening for OAG. 

Screening may be a good way to find and treat more people who have OAG. Screening involves inviting everybody who has a particular characteristic, for example of a certain age, for testing. However, we need to know that screening will reduce the number of people losing vision and that it is value for money compared with the current system of people choosing to attend for a sight test. To answer these questions we need a large, high quality research study, i.e. a randomised controlled trial (RCT).

Before we can conduct a screening RCT we have to determine which screening tests should be evaluated, where testing should take place and who to include. Also we need to know how best to measure benefits and any harms of screening. 

We will seek the views of people who do and do not have glaucoma, as well as views of health care professionals involved in providing eye care services.</gtr:abstractText><gtr:technicalSummary>Open angle glaucoma (OAG) is a primary, progressive optic neuropathy; the onset is asymptomatic, progression occurs silently until the disease is moderately advanced when vision is affected. Blindness due to OAG is irreversible. It is suggested that OAG may be a condition that fulfils the criteria for population screening. Two recent studies, based on economic modelling evaluations and reviews of the literature, suggest that screening in higher-risk groups might be worthwhile. Both these studies highlighted the considerable uncertainties in the available primary data and that further research is required to inform decisions on whether a screening programme should be initiated. A RCT is the optimal design to determine whether screening is effective, and no such RCT has been undertaken. Prior to initiating a RCT further research is required to inform the trial design, specifically the optimal screening approach and how outcome should be determined. This is what this proposed study aims to do.
A mixed method, multidisciplinary approach will be used to address the following research questions:
1. What screening strategy (i.e., test; site; target population; provider) will give the optimal combination of feasibility and acceptability to providers?
2. How feasible are the proposed identification strategies for each at-risk group and, given the results, what is the most appropriate unit of clustering?
3. What are the most likely effective interventions for maximising screening attendance by the targeted individuals?
4. What are the most appropriate methods for obtaining primary clinical and patient reported outcomes for use in the trial?

This research will deliver an acceptable screening strategy; feasible strategies to invite each of the target groups; informed trial design (unit of clustering); a decision as to whether a behavioural intervention might increase uptake of screening; an updated economic model to inform the RCT; defined trial outcomes. This research will thus enable a precise and evidence-based trial protocol to be developed that has the best opportunity to demonstrate the success or not of a glaucoma screening programme. 

The study will be led from the Health Services Research Unit and the Health Economics Research Unit, University of Aberdeen and involves collaborators across the UK and Europe. The lead centre has long term infrastructure funding, making the ideal environment for undertaking this study and any definitive screening trial with long term follow up.</gtr:technicalSummary><gtr:fund><gtr:end>2010-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>408886</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Comprehensive Clinical Trials Unit</gtr:department><gtr:description>Applied Clinical Trials Centre Investigating Vision and Eyes</gtr:description><gtr:id>137731EC-24ED-4E35-B5B1-9C39CDB296DD</gtr:id><gtr:impact>Funded NIHR portfolio studies. The team is multidisciplinary</gtr:impact><gtr:outcomeId>545b608211fe75.90693326-2</gtr:outcomeId><gtr:partnerContribution>The group is a collaborative ophthalmology resource for the design, conduct, analysis and reporting of randomised controlled clinical trials of important questions for eye health and vision brining together context ( ophthalmology) and intellectual expertise in systematic reviews, statistics, economics and triallists.</gtr:partnerContribution><gtr:piContribution>I am executive chair of the collaborative partnership between University of St Andrews and Moorfields BRC. I have brought expertise in the design , conduct and reporting of clinical trials. ACTIVE has a formal collaboration agreement with the UCL-Comprhensive Clinical Trails Unit</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Government of Finland</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>Finland</gtr:description><gtr:id>328E542A-14D3-4AE4-8E77-AF40E21CF8A8</gtr:id><gtr:impact>The Finnsh government have funded a pilot study in Finland to explore how our findings may be applied in a Finnish context. The PI and one co-investigator on the glaucoma platform study are on the advisory panel. The Finnish project will start in 2011.</gtr:impact><gtr:outcomeId>pa85uyzcAwW-1</gtr:outcomeId><gtr:partnerContribution>Insight into how the outputs from this research in the UK context may be applied in a Finnish context.</gtr:partnerContribution><gtr:piContribution>The preliminary outputs of the research have been presented at international meetings; this has stimulated collaborators and patient organisations to contact us regarding future collaboration.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Glaucoma Australia</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Australia</gtr:description><gtr:id>ABAFE55A-EE62-4301-A467-294D62E75827</gtr:id><gtr:impact>The committee on glaucoma detection reporting to the board of Glaucoma Australia (a patient organisation) have sought a collaboration with the Dr Burr and the outputs of the glaucoma screening platform study. Glaucoma Austraila are funding Dr Burr to visit Sydney in 2011 to discuss the details of future potential collaborations. This will be a multidisciplinary collaboration involving clinicans (optometrists, nurses and ophthalmologists), patients and clinical scientists,</gtr:impact><gtr:outcomeId>iCr9rb4aL64-1</gtr:outcomeId><gtr:partnerContribution>Insight into how the outputs from our research in the UK context may be applied in an Australian context,</gtr:partnerContribution><gtr:piContribution>The preliminary outputs of the research have been presented at international meetings; this has stimulated collaborators and patient organisations to contact us regarding future collaboration.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Moorfields Eye Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>EPIC study (Professor Paul Foster)</gtr:description><gtr:id>35076D5A-F523-497F-81EA-036C6C0043D3</gtr:id><gtr:impact>MRC ?Fight for Sight pre-doctoral fellowship</gtr:impact><gtr:outcomeId>FHpD2hLQcpS-1</gtr:outcomeId><gtr:partnerContribution>The partnership provides additional information to inform the policy question of glaucoma screening or enhanced case detection</gtr:partnerContribution><gtr:piContribution>The European Prospective Investigation of Cancer (EPIC) study is a large multi-centre cohort study looking at the connection between diet and cancer.The EPIC-Norfolk cohort, consists of 30,446 men &amp;amp; women, was established in 1993. Since 2004, detailed eye examination data on 6,277 subjects aged 49 years and older have been gathered, and examination on 8,000 subjects is complete The data includes among others, parameters for glaucoma assessment, such as visual acuity, intraocular pressure, retinal nerve fibre layer imaging with scanning laser polarimetry, optic nerve head tomography with Heidelberg HRT2, as well as disc &amp;amp; macular digital photographs. I am a collaborator and advisor to a MRC /Fight for sight funded fellowsip. The fellow is exploring the Ophthalmology data nested in the EPIC-Norfolk cohort. togther we are exploring how these data can be used to address the policy question of the value of glaucoma screening.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Moorfields Eye Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Moorfields Biomedical Research Centre</gtr:department><gtr:description>Applied Clinical Trials Centre Investigating Vision and Eyes</gtr:description><gtr:id>7A6D09C5-E564-46B8-9DDE-9D4BA718E91A</gtr:id><gtr:impact>Funded NIHR portfolio studies. The team is multidisciplinary</gtr:impact><gtr:outcomeId>545b608211fe75.90693326-1</gtr:outcomeId><gtr:partnerContribution>The group is a collaborative ophthalmology resource for the design, conduct, analysis and reporting of randomised controlled clinical trials of important questions for eye health and vision brining together context ( ophthalmology) and intellectual expertise in systematic reviews, statistics, economics and triallists.</gtr:partnerContribution><gtr:piContribution>I am executive chair of the collaborative partnership between University of St Andrews and Moorfields BRC. I have brought expertise in the design , conduct and reporting of clinical trials. ACTIVE has a formal collaboration agreement with the UCL-Comprhensive Clinical Trails Unit</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Patient group meeting (IGA)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B245C4A8-43F3-4B50-90D1-96CED77209AC</gtr:id><gtr:impact>About 50 people with glaucoma attended this patient day . I was talking about screening for glaucoma and the potential benefits and pitfalls of any glaucoma screening programme. 
JB is speaking at the IGA Scotland National Glaucoma Patient Meeting 25th October 2013. Future glaucoma care (What the evidence suggests)

Information for the public on the International Glaucoma Association website, about how screening may not be the way forward to improve glaucoma detection but interventions to maximise uptake by those who do not seek are and improved detection by health care professionals is indicated.</gtr:impact><gtr:outcomeId>FnXirgH84zg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.glaucoma-association.com/uploads/Newsletters/Spring%20News%202013%20Web%204MB.pdf</gtr:url><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK Glaucoma Alliance</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0C2D017A-F20F-4E1E-A4F2-022F66FBD2BF</gtr:id><gtr:impact>Two researchers presented the outline of the whole study and described the interviews undertaken with health care providers to develop the Glaucoma screening intervention for the future trial.

The presentation was on the 20th November 2009. The anticipated impact will be dissemination of information about the future research agenda to evaluate screening for glaucoma.</gtr:impact><gtr:outcomeId>8F67B059C57</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public health and community eye care</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9B822F21-6212-42DB-AD28-EF066BB8F3AA</gtr:id><gtr:impact>Around 30 people, including users with sight loss, community optometrists, ophthalmologists and public health physicians and representatives from RNIB Scotland attended this workshop. The aim was to discuss initiatives to reduce sight loss from blinding eye disease in Scotland and to explore implementation.

I am in discussions with RNIB and the International Glaucoma Association on funding for future implementation research on enhanced glaucoma case detection.</gtr:impact><gtr:outcomeId>B1SmTCmsEYW</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>357236</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2010-07-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>24221F47-37BA-461F-BA3C-778749CD5068</gtr:id><gtr:outcomeId>EBKusfqP39t0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Visiting Fellowship</gtr:description><gtr:end>2010-08-02</gtr:end><gtr:fundingOrg>Chief Scientist Office (CSO)</gtr:fundingOrg><gtr:id>BA681C65-0281-4687-9AB0-014846C306CF</gtr:id><gtr:outcomeId>HAYF3ojwKLc0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The mixed methods study has developed the clinical components of the clinical testing strategy following the MRC framework for the development of complex interventions; additionally the components of a behavioural intervention to maximise attendance for glaucoma screening have been developed.</gtr:description><gtr:id>21C1DC3F-CF4B-45A0-8DA1-079E0DEF9210</gtr:id><gtr:impact>The developed interventions will be evaluated in a future randomised controlled trial evaluating glaucoma screening or ehanced glaucoma case detection.</gtr:impact><gtr:outcomeId>HCH8a5rzzMU</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Public health intervention</gtr:title><gtr:type>Preventative Intervention - Behavioural risk modification</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A 71 A Pilot glaucoma specific patient reported outcome measure has been developed</gtr:description><gtr:id>EF819224-BFA4-4528-B7D7-E4A63E7D329B</gtr:id><gtr:impact>The pilot instrument is in the process of validation. The final instrument will be an important measure for clinical practice and research.</gtr:impact><gtr:outcomeId>c7vKXSToHfr</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Aberdeen Glaucoma Questionnaire</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AC5943E3-4FF5-4ADA-9099-A7F43D3A3BDE</gtr:id><gtr:title>Developing the clinical components of a complex intervention for a glaucoma screening trial: a mixed methods study.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/343d3603130ac657d333d15d1716ce2a"><gtr:id>343d3603130ac657d333d15d1716ce2a</gtr:id><gtr:otherNames>Glaucoma screening Platform Study group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>FA073127_6FA073127_6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>704622A0-9E1A-424E-9B64-D52C8423972D</gtr:id><gtr:title>Why do people present late with advanced glaucoma? A qualitative interview study.</gtr:title><gtr:parentPublicationTitle>The British journal of ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb58597f83b3922d258e3db79cb2fe51"><gtr:id>eb58597f83b3922d258e3db79cb2fe51</gtr:id><gtr:otherNames>Prior M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1161</gtr:issn><gtr:outcomeId>doi_14520_013_303813</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2D61E5F-AFC3-4AA3-A2AD-DB96EE0A35B6</gtr:id><gtr:title>Developing the specifications of an open angle glaucoma screening intervention in the United Kingdom: a Delphi approach.</gtr:title><gtr:parentPublicationTitle>BMC health services research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65c1366031313ac002ea9d28169c4b72"><gtr:id>65c1366031313ac002ea9d28169c4b72</gtr:id><gtr:otherNames>Campbell SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1472-6963</gtr:issn><gtr:outcomeId>pm_14520_20_23216983</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8C907CA-A4A7-45D4-BE69-8D9A02BA947B</gtr:id><gtr:title>Gradually Then Suddenly? Decline in Vision-Related Quality of Life as Glaucoma Worsens.</gtr:title><gtr:parentPublicationTitle>Journal of ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59ac40b969c64db850e438e12bb3e323"><gtr:id>59ac40b969c64db850e438e12bb3e323</gtr:id><gtr:otherNames>Jones L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2090-004X</gtr:issn><gtr:outcomeId>5a2fd761a46722.38048924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26CA147A-7FFF-45AC-9F69-6D3B9788DC3F</gtr:id><gtr:title>Theoretical and empirical dimensions of the Aberdeen Glaucoma Questionnaire: a cross sectional survey and principal component analysis.</gtr:title><gtr:parentPublicationTitle>BMC ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb58597f83b3922d258e3db79cb2fe51"><gtr:id>eb58597f83b3922d258e3db79cb2fe51</gtr:id><gtr:otherNames>Prior M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2415</gtr:issn><gtr:outcomeId>pm_14520_20_24268026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8ADD65E0-F3B3-4163-9647-2A3BC213D325</gtr:id><gtr:title>Is it worthwhile to conduct a randomized controlled trial of glaucoma screening in the United Kingdom?</gtr:title><gtr:parentPublicationTitle>Journal of health services research &amp; policy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c599d1975d684b4f62383d656e93df12"><gtr:id>c599d1975d684b4f62383d656e93df12</gtr:id><gtr:otherNames>Burr J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1355-8196</gtr:issn><gtr:outcomeId>doi_14520_9613499748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6A67A45-DDF8-496B-9545-850134E31A68</gtr:id><gtr:title>Choosing appropriate patient-reported outcomes instrument for glaucoma research: a systematic review of vision instruments.</gtr:title><gtr:parentPublicationTitle>Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e74d1de30b1c6dc4c6dd457c70b1532d"><gtr:id>e74d1de30b1c6dc4c6dd457c70b1532d</gtr:id><gtr:otherNames>Che Hamzah J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0962-9343</gtr:issn><gtr:outcomeId>XJBn6j36ZwC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3095A5A-0022-4554-8002-D161FF5D5A09</gtr:id><gtr:title>Evidence base for an intervention to maximise uptake of glaucoma testing: a theory-based cross-sectional survey.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb58597f83b3922d258e3db79cb2fe51"><gtr:id>eb58597f83b3922d258e3db79cb2fe51</gtr:id><gtr:otherNames>Prior M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>pz4uYoqDqEF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4F2FBD4-C8A0-47AA-8D53-D4041A4BE132</gtr:id><gtr:title>Pre-validation methods for developing a patient reported outcome instrument.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b22b2749fc582772c0b9707cf01d2f2f"><gtr:id>b22b2749fc582772c0b9707cf01d2f2f</gtr:id><gtr:otherNames>Prior ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>nvzYfPsGb4K</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701759</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5C2ACE0A-A29E-4DCC-9F5A-B00BFAB172B9</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.4  Population screening</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>